Indian biotech startups focused on novel drug discovery are struggling to attract long-term capital, which is currently skewed toward manufacturing and established businesses. While the government’s upcoming ₹10,000-crore Biopharma Shakti programme aims to support the sector, the mismatch between high R&D risks and existing investor timelines remains a significant hurdle.
The Indian biotechnology sector is experiencing a significant imbalance in how capital is distributed. While established pharmaceutical manufacturing and Contract Research and Development Manufacturing Organizations (CRDMOs) continue to attract substantial investment due to their proven revenue models and quicker returns, startups focused on novel drug discovery are struggling to secure the necessary funding. This creates a difficult environment for companies attempting to develop new, proprietary molecules from the ground up.
For investors, the distinction between manufacturing-led biotech and innovation-led biotech is important. Manufacturing firms generally carry lower risk, as they operate in well-defined markets with predictable cash flows. In contrast, novel drug development is a long, capital-intensive process that carries high execution risk. Many early-stage startups find that local venture capital ecosystems are not designed to support the lengthy gestation periods—often lasting a decade or more—required for successful drug approval and commercialization.
To address this, there is growing industry demand for state-backed risk-sharing mechanisms. Proponents argue that government co-investment could act as a buffer, making it safer for private investors to support high-risk incubation projects. The upcoming ₹10,000-crore Biopharma Shakti programme is being watched closely by the industry, as it aims to provide a more integrated pipeline for research and development, connecting academic laboratories with the commercial pharmaceutical industry.
Beyond funding, the industry also faces hurdles related to regulatory and intellectual property frameworks. Global players often require strong, consistent policies on data protection and pricing before committing to significant research spending in the country. Additionally, India's market environment, characterized by high out-of-pocket spending and relatively low health insurance penetration, can make it challenging for companies to commercialize expensive, innovative drugs domestically. This often leads innovators to seek international funding or move their research activities abroad, which can limit the growth of local research capabilities.
The path forward for the sector depends on how effectively these structural gaps are closed. The primary monitorables for investors tracking this space include the rollout and efficacy of the Biopharma Shakti programme, updates to intellectual property regulations, and whether there is an increase in patient capital specifically aimed at long-term drug development cycles. For now, the innovation-led biotech space remains a high-risk segment that requires investors to evaluate companies based on long-term clinical trial progress and policy support, rather than immediate revenue growth.